Riik: Austraalia
keel: inglise
Allikas: Department of Health (Therapeutic Goods Administration)
telmisartan, Quantity: 80 mg
Alphapharm Pty Ltd
Telmisartan
Tablet, uncoated
Excipient Ingredients: meglumine; povidone; sodium hydroxide; magnesium stearate; mannitol
Oral
56, 98, 28, 7
(S4) Prescription Only Medicine
TELMISARTAN MYLAN is indicated for:,? Treatment of hypertension,? Prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage (see CLINICAL TRIALS)
Visual Identification: White to off white, oblong, biconvex tablets debossed with 'TN80' on one side and 'M' on the other side.; Container Type: Blister Pack; Container Material: PA/Al/PVC/Al - polyamide-aluminium foil-polyvinylchloride/aluminium foil; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Licence status A
2014-01-08
MIZART 1 TELMISARTAN MYLAN TABLETS _contains the active ingredient Telmisartan_ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about TELMISARTAN MYLAN. It does not contain all available information. It does not take the place of talking to your doctor or pharmacist. This leaflet was last updated on the date at the end of this leaflet. More recent information may be available. The latest Consumer Medicine Information is available from your pharmacist, doctor, or from www.medicines.org.au and may contain important information about the medicine and its use of which you should be aware. KEEP THIS INFORMATION WITH YOUR TELMISARTAN MYLAN TABLETS. You may need to read it again later. _TO FIND OUT MORE ABOUT _ _TELMISARTAN MYLAN_ ASK YOUR DOCTOR OR PHARMACIST IF YOU HAVE ANY QUESTIONS ABOUT YOUR MEDICINE OR IF YOU HAVE ANY TROUBLE BEFORE, DURING OR AFTER USING TELMISARTAN MYLAN. WHAT TELMISARTAN MYLAN IS USED FOR TELMISARTAN MYLAN is used to: treat high blood pressure (also called hypertension). prevent cardiovascular complications, including death due to cardiovascular causes, in patients older than 55 years of age with coronary artery disease, peripheral vascular disease, previous stroke, previous transient ischaemic attack (TIA) or high risk diabetes with evidence of end organ damage. _TREATMENT OF HYPERTENSION_ TELMISARTAN MYLAN is used to lower high blood pressure (also called hypertension). Everyone has blood pressure. This pressure helps your blood move around your body. Your blood pressure may be different at different times of the day, depending on how busy or worried you are. You have hypertension when your blood pressure stays higher than normal, even when you are calm or relaxed. There are usually no signs of hypertension. The only way of knowing that you have hypertension is to have your blood pressure checked on a regular basis. You may feel fine and have no symptoms, but if high blood pressure is not treated, it can lead to serious health problems Lugege kogu dokumenti
MIZART ® _Telmisartan _ PRODUCT INFORMATION NAME OF THE MEDICINE Active ingredient : telmisartan Chemical name : 4’-[(1,4’-dimethyl-2’-propyl[2,6’-bi-1H-benzimidazol]-1’-yl)-methyl][1,1’- biphenyl]-2-carboxylic acid (IUPAC nomenclature) Structural formula : Molecular formula : C 33 H 30 N 4 O 2 Molecular weight : 514.6 CAS Registry no. : 144701-48-4 DESCRIPTION Telmisartan is a specific angiotensin II receptor (type AT1) antagonist. Telmisartan is an off-white to yellowish crystalline powder. It is practically insoluble in water, very slightly soluble in ethanol, slightly soluble in methanol and soluble in a mixture of chloroform and methanol (1:1). MIZART ® is available as tablets for oral administration. Tablets containing 40 mg and 80 mg of telmisartan are available. The excipients are mannitol, sodium hydroxide, meglumine, povidone and magnesium stearate PHARMACOLOGY PHARMACODYNAMICS Telmisartan displaces angiotensin II with very high affinity from its binding site at the AT1 receptor subtype, which is responsible for the known actions of angiotensin II. Telmisartan does not exhibit any partial agonist activity at the AT1 receptor. Telmisartan binds selectively with the AT1 receptor and does not reveal relevant affinity for other receptors nor does it inhibit human plasma renin or block ion channels. The clinically relevant effect of AT1 receptor blockade is to lower blood pressure by inhibition of angiotensin II mediated vasoconstriction leading to reduction of systemic vascular resistance. During administration with telmisartan, removal of angiotensin II negative feedback on renin secretion results in increased plasma renin activity, which in turn leads to increases in angiotensin II in plasma. Despite these increases, antihypertensive activity and suppressed aldosterone levels indicate effective angiotensin II receptor blockade. Telmisartan does not inhibit angiotensin converting enzyme (kininase II), the enzyme which also degrades bradykinin. Therefore it is not expected to potentiate bradyk Lugege kogu dokumenti